Enhancing NSCLC Neoadjuvant Therapy
A panel deliberates post-neoadjuvant strategies and data requirements for optimizing immune checkpoint inhibitors in NSCLC neoadjuvant therapy.
David Carbone Martin Dietrich Patrick Forde Non Small Cell Lung Cancer Advanced Disease Early Stage Disease
Source: ajmc.com